Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2008-12-22
2011-12-13
Haddad, Maher (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S192100, C514S021200
Reexamination Certificate
active
08075894
ABSTRACT:
The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders.
REFERENCES:
patent: 1033401 (2000-09-01), None
patent: WO 02/098917 (2002-12-01), None
Mizuhara et al. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology. Jun. 1996;23(6):1608-15.
Attwood TK. Genomics. The Babel of bioinformatics. Science. 290(5491):471-473, 2000.
Altschul, S.F. et al. “Basic Local Alignment Search Tool,”J. Mol. Biol., 1990, pp. 403-410, vol. 215.
Altschul, S.F. et al. “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,”Nucleic Acids Research, 1997, pp. 3389-3402, vol. 25, No. 17.
Anthony-Cahill, S.J. and Magliery, T.J. “Expanding the Natural Repertoire of Protein Structure and Function,”Current Pharmaceutical Biotechnology, 2002, pp. 299-315, vol. 3.
Armaleo, D. et al. “Biolistic nuclear transformation ofSaccharomyces cerevisiaeand other fungi,”Curr Genet, 1990, pp. 97-103, vol. 17.
Brown, A.R. et al. “The Total Chemical Synthesis of Monocyte Chemotactic Protein-1 (MCP-1),”Journal of Peptide Science, 1996, pp. 40-46, vol. 2.
Brutlag, D.L. et al. “Improved sensitivity of biological sequence database searches,”Comput Appl Biosci, 1990, pp. 237-245, vol. 6, No. 3.
Casi, G. and Hilvert, D. “Convergent protein synthesis,”Current Opinion in Structural Biology, 2003, pp. 589-594, vol. 13.
Chai, H. et al. “Glycosylation and high-level secretion of human tumour necrosis factor-β in recombinant baculovirus-infected insect cells,”Biotechnol. Appl. Biochem., 1993, pp. 259-273, vol. 18.
Chan, J.Y.-H. et al. “Relationship between Novel Isoforms, Functionally Important Domains, and Subcellular Distribution of CD164/Endolyn,”The Journal of Biological Chemistry, Jan. 19, 2001, pp. 2139-2152, vol. 276, No. 3.
Clark, A.J. “The Mammary Gland as a Bioreactor: Expression, Processing, and Production of Recombinant Proteins,”Journal of Mammary Gland Biology and Neoplasia, 1998, pp. 337-350, vol. 3, No. 3.
Cleland, J.L. “The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation,”Critical Reviews in Therapeutic Drug Carrier Systems, 1993, pp. 307-377, vol. 10, No. 4.
Cleland, J.L. “Emerging protein delivery methods,”Current Opinion in Biotechnology, 2001, pp. 212-219, vol. 12.
Cunningham, B.C. and Wells, J.A. “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science, Jun. 2, 1989, pp. 1081-1085, vol. 244.
Dougherty, D.A. “Unnatural amino acids as probes of protein structure and function,”Current Opinion in Chemical Biology, 2000, pp. 645-652, vol. 4.
Doyonnas, R. et al. “CD164 Monoclonal Antibodies That Block Hemopoietic Progenitor Cell Adhesion and Proliferation Interact with the First Mucin Domain of the CD164 Receptor,”The Journal of Immunology, 2000, pp. 840-851, vol. 165.
Feldman, L.J. “Adenovirus-mediated arterial gene therapy for restenosis: problems and perspectives,”Semin Intervent Cardiol, 1996, pp. 203-208, vol. 1.
Gendel, S.M. “Sequence Analysis for Assessing Potential Allergenicity,”Annals New York Academy of Sciences, 2002, pp. 87-98, vol. 964.
Gentz, R. “Bioassay for trans-activation using purified human immunodeficiency virustat-encoded protein: Trans-activation requires mRNA synthesis,”Proc. Natl. Acad. Sci. USA, Feb. 1989, pp. 821-824, vol. 86.
Gish, W. and States, D.J. “Identification of protein coding regions by database similarity search,”Nature Genetics, Mar. 1993, pp. 266-272, vol. 3.
Golebiowski, A. et al. “High-throughput organic synthesis of peptide mimetics,”Current Opinion in Drug Discovery and Development, 2001, pp. 428-434, vol. 4, No. 4.
Gonnet, G.H. et al. “Exhaustive Matching of the Entire Protein Sequence Database,”Science, Jun. 5, 1992, pp. 1443-1445, vol. 256.
Gor, D.O. et al. “TH1-TH2: a Procrustean paradigm,”Nature Immunology, Jun. 2003, pp. 503-505, vol. 4, No. 6.
Graddis, T.J. et al. “Designing Proteins That Work Using Recombinant Technologies,”Current Pharmaceutical Biotechnology, 2002, pp. 285-297, vol. 3.
Gustafsson, C. et al. “Codon bias and heterologous protein expression,”TRENDS in Biotechnology, Jul. 2004, pp. 346-353, vol. 22, No. 7.
Henikoff, S. and Henikoff, J.G. “Performance Evaluation of Amino Acid Substitution Matrices,”Proteins: Structure, Function, and Genetics, 1993, pp. 49-61, vol. 17.
Herrick, C.A. and Bottomly, K. “To Respond or Not to Respond: T Cells in Allergic Asthma,”Nat Rev Immunol, May 2003, pp. 405-412, vol. 3.
Higgins, D.G. et al. “Using CLUSTAL for Multiple Sequence Alignments,”Methods in Enzymology, 1996, pp. 383-402, vol. 266.
Hruby, V.J. and Balse, P.M. “Conformational and Topographical Considerations in Designing Agonist Peptidomimetics from Peptide Leads,”Current Medicinal Chemistry, 2000, pp. 945-970, vol. 7.
Karlin, S. and Altschul, S.F. “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes,”Proc Natl Acad Sci USA, Mar. 1990, pp. 2264-2268, vol. 87.
Lee, Y.-N. et al. “Identification of a Role for the Sialomucin CD164 in Myogenic Differentiation by Signal Sequence Trapping in Yeast,”Molecular and Cellular Biology, Nov. 2001, pp. 7696-7706, vol. 21, No. 22.
Lenhard, T. et al. “A new set of versatile vectors for the heterologous expression of foreign genes using the baculovirus system,”Gene, 1996, pp. 187-190, vol. 169.
Luo, Y. and Prestwich, G. “Novel biomaterials for drug delivery,”Expert Opin. Ther. Patents, 2001, pp. 1395-1410, vol. 11, No. 9.
Malik, F. et al. “Polyethylene Glycol (PEG)-modified Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) with Conserved Biological Activity,”Exp. Hematol., 1992, pp. 1028-1035, vol. 20.
Marshall, S.A. et al. “Rational design and engineering of therapeutic proteins,”Drug Discov Today, Mar. 2003, pp. 212-221, vol. 8, No. 5.
Matsui, T. et al. “The Ratio of Splicing Variants of MGC-24/CD164, a Sialomucin, Correlates with the Metastatic Potential of Colorectal Carcinomas,”J. Biochem, 2000, pp. 1103-1107, vol. 127, No. 6.
Muir, T.W. “Semisynthesis of Proteins by Expressed Protein Ligation,”Annu. Rev. Biochem., 2003, pp. 249-289, vol. 72.
Murphy, L.R. et al. “Simplified amino acid alphabets for protein fold recognition and implications for folding,”Protein Engineering, 2000, pp. 149-152, vol. 13, No. 3.
Nicolau, C. et al. “Liposomes as Carriers for in Vivo Gene Transfer and Expression,”Methods in Enzymology, 1987, pp. 157-176, vol. 149.
Ohno, T. et al. “Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury,”Science, Aug. 5, 1994, pp. 781-784, vol. 265.
Pearson, W.R. and Lipman, D.J. “Improved tools for biological sequence comparison,”Proc Natl Acad Sci USA, Apr. 1988, pp. 2444-2448, vol. 85.
Pillai, O. and Panchagnula, R. “Polymers in drug delivery,” Current Opinion in Chemical Biology, 2001, pp. 447-451, vol. 5.
Rogov, S.I. and Nekrasov, A.N. “A numerical measure of amino acid residues similarity based on the analysis of their surroundings in natural protein sequences,”Protein Engineering, 2001, pp. 459-463, vol. 14, No. 7.
Schellekens, H. “Bioequivalence and the Immunogenicity of Biopharmaceuticals,”Nat Rev Drug Discov, Jun. 2002, pp. 457-462, vol. 1.
Smith, G.E. et al. “Production of Human Beta Interferon in Insect
Haddad Maher
Merck Serono SA
Saliwanchik Lloyd & Eisenschenk
LandOfFree
Use of soluble CD164 in inflammatory and/or autoimmune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of soluble CD164 in inflammatory and/or autoimmune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of soluble CD164 in inflammatory and/or autoimmune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296203